$-0.04
(Market cap
$17 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
1.4
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-1.3 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
0.9
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$-12.6
-
Face value
--
-
Shares outstanding
3,207,810
6 Years Aggregate
CFO
$-462.34 Mln
EBITDA
$-543.77 Mln
Net Profit
$-609.53 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Passage Bio (PASG)
| -53.3 | -5.7 | -36.4 | -25.5 | -35.3 | -54.5 | -- |
|
BSE Sensex
| -10.4 | -1.0 | -7.8 | -7.7 | 6.7 | 8.3 | 11.1 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
|---|---|---|---|---|---|
|
Passage Bio (PASG)
| 4.0 | -43.6 | -26.8 | -78.3 | -75.2 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Passage Bio (PASG)
|
5.5 | 16.8 | 0.0 | -37.7 | -- | -175.8 | -- | 1.4 |
| 79.0 | 10,557.2 | 622.0 | -300.9 | -25.7 | -61.1 | -- | 17.3 | |
| 77.5 | 10,446.2 | 105.8 | -829.6 | -715.0 | -- | -- | 60.3 | |
| 50.5 | 12,605.5 | 2,375.5 | 833.4 | 40.8 | 40.7 | 16.6 | 6.4 | |
| 124.6 | 15,772.8 | 1,080.2 | -433.2 | -39.8 | -- | -- | 55.7 | |
| 69.9 | 8,103.6 | 1,508.5 | 348.8 | 57.0 | 96.4 | 24 | 36.9 | |
| 305.5 | 8,827.7 | 417.3 | 225.0 | 42.8 | 18.6 | 40 | 6.9 | |
| 526.7 | 11,925.8 | 1,132.5 | -309.4 | -25.5 | -52.9 | -- | 22.0 | |
| 430.7 | 12,360.6 | 2,678.3 | 460.4 | 21.1 | 103.2 | 27.3 | 20.7 | |
| 355.5 | 9,578.0 | 0.0 | -326.5 | -- | -37.2 | -- | 6.8 |
Shareholding Pattern
View DetailsAbout Passage Bio (PASG)
Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin... deficiency; PBGM01, a functional GLB1 gene encoding ß-galactosidase for infantile GM1; and PBKR03, for the treatment of Krabbe disease. The company develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and other programs for huntington's disease. It has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. Passage Bio, Inc. was incorporated in 2017 and is based in Philadelphia, Pennsylvania. Address: One Commerce Square, Philadelphia, PA, United States, 19103 Read more
-
President, CEO & Director
Dr. William Chou M.D.
-
President, CEO & Director
Dr. William Chou M.D.
-
Headquarters
Philadelphia, PA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Passage Bio (PASG)
What is the current share price of Passage Bio Inc (PASG) Today?
The share price of Passage Bio Inc (PASG) is $5.51 (NASDAQ) as of 27-May-2026 12:27 EDT. Passage Bio Inc (PASG) has given a return of -35.27% in the last 3 years.
What is the current PB & PE ratio of Passage Bio Inc (PASG)?
Since, TTM earnings of Passage Bio Inc (PASG) is negative, P/E ratio is not available.
The P/B ratio of Passage Bio Inc (PASG) is 1.43 times as on 22-May-2026, a 66 discount to its peers’ median range of 4.24 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
-0.78
|
1.89
|
|
2024
|
-0.03
|
0.03
|
|
2023
|
-0.03
|
0.03
|
|
2022
|
-0.03
|
0.02
|
|
2021
|
-0.10
|
0.06
|
What is the 52 Week High and Low of Passage Bio Inc (PASG)?
The 52-week high and low of Passage Bio Inc (PASG) are Rs 20.00 and Rs 3.94 as of 27-May-2026.
What is the market cap of Passage Bio Inc (PASG)?
Passage Bio Inc (PASG) has a market capitalisation of $ 17 Mln as on 22-May-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Passage Bio Inc (PASG)?
Before investing in Passage Bio Inc (PASG), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.